- Home
- CTCX
CTCX
Carmell Corporation
as 11-15-2024 9:42am EST
Carmell Corp is a bio-aesthetics company that utilizes the Carmell Secretome to support skin and hair health. Its cosmetic skincare product portfolio includes Carmell G.L.E.E and various others in pipeline such as Youth restoring formula, Ultra-brightening formula, Ultra-hydrating formula, and Rapid Recovery formula among others. The company has one operating segment, principally the business of developing and commercializing bio-aesthetics and its bone and tissue healing products.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 10.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $4.31 | Next Earning Date: | 11-22-2024 |
| Revenue: | $12,320 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Carmell Corporation News
CTCX Breaking Stock News: Dive into CTCX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Carmell Corporation Launches Skincare Partnership With Ladies Playbook to Support and Celebrate NFL Sports Community
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/23/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/22/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/21/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/20/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/19/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/16/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/15/2024
Compare CTCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTCX Carmell Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.